UPDATE: Feltl & Company Raises PT to $22.10 on Insulet

Feltl & Company reiterates its Buy rating on Insulet

and increased its price target to $22.10 from $18.60 on better than expected guidance for revenues in 2012. Feltl & Company notes, "Insulet reported EPS of ($0.30) versus our ($0.27) estimate and ($0.26) consensus. Reported revenue came in at $47.2 million versus our $47.0 million estimate and $47.4 million consensus. Management guided 2012 revenue to a range of $210-$225 million versus our previous $207.7 million estimate. In addition, the company guided to a cash operating loss of ($10) million to breakeven, which was below our previous estimate of $8.2 million." PODD closed at $19.95 a share on Thursday.